Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Related Posts
Wall Street has mixed feelings toward European stocks for 2025. Here are their big calls
While some banks are bearish, and expect a decline, others are forecasting high single digit gains for the Stoxx Europe 600 index.
Dow futures jump 400 points as traders await details on U.S.-China trade deal: Live updates
Trump administration announced a “trade deal” with China following negotiations over the weekend in Switzerland.
Wall Street reacts to Trump’s tariff announcement as the stock market drops
Investors and strategists warn that the tariffs could hurt economic growth, but some said Trump’s move may be a “negotiation tactic.”